Locally administered ocular corticosteroids: benefits and risks.
about
Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular PressureDry eye: an inflammatory ocular diseaseCorneal nerves in health and diseaseLoteprednol and tobramycin in combination: a review of their impact on current treatment regimens.Reducing peak corneal haze after photorefractive keratectomy in rabbits: prednisolone acetate 1.00% versus cyclosporine A 0.05%Controlling viral immuno-inflammatory lesions by modulating aryl hydrocarbon receptor signalingEfficacy and safety of indomethacin 0.1% eye drops compared with ketorolac 0.5% eye drops in the management of ocular inflammation after cataract surgery.Soluble vascular endothelial growth factor receptor-3 suppresses allosensitization and promotes corneal allograft survival.Corneal lymphangiogenesis in herpetic stromal keratitisTreatment with melatonin after onset of experimental uveitis attenuates ocular inflammation.An anti-inflammatory role of VEGFR2/Src kinase inhibitor in herpes simplex virus 1-induced immunopathology.Severe infective keratitis leading to hospital admission in New ZealandTopical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease.A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgeryThe Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery.An update on the use of ophthalmic ketorolac tromethamine 0.4%.The Toxicity of Nonsteroidal Anti-inflammatory Eye Drops against Human Corneal Epithelial Cells in Vitro.Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.Comparison of effect of nepafenac and diclofenac ophthalmic solutions on cornea, tear film, and ocular surface after cataract surgery: the results of a randomized trial.Steroid-induced ptosis: case studies and histopathologic analysis.Neuroprotectin D1 reduces the severity of herpes simplex virus-induced corneal immunopathologyPharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle DogsControlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution.Keratoconjunctivitis sicca manifestations in ocular graft versus host disease: pathogenesis, presentation, prevention, and treatment.Management of seasonal allergic conjunctivitis: guide to therapy.Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same?Contact lenses as drug reservoirs & delivery systems: the successes & challenges.Iatrogenic Cushing syndrome caused by ocular glucocorticoids in a child.The Role of Alpha-MSH as a Modulator of Ocular Immunobiology Exemplifies Mechanistic Differences between Melanocortins and Steroids.Management of High-risk Corneal Transplantation.An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis.Triamcinolone acetonide nanoparticles incorporated in thermoreversible gels for age-related macular degeneration.Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature.Approaches in topical ocular drug delivery and developments in the use of contact lenses as drug-delivery devices.Different cellular effects of four anti-inflammatory eye drops on human corneal epithelial cells: independent in active components.Frontline Science: Aspirin-triggered resolvin D1 controls herpes simplex virus-induced corneal immunopathology.Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
P2860
Q26764956-CFADF8CB-6C50-4F4B-9B89-183FA06F0906Q26852044-6F474BB3-F190-4267-9BEF-A8A9085676AFQ27002347-6B094589-188C-4F16-AF28-5AC37C6FD17AQ33538277-C4F4C84E-71A5-46A1-80DC-FDBD44B25183Q33846813-C348CD65-F3C6-4A2A-8BFE-FAAE0F8855D0Q34102743-801224FC-8CE2-4D47-BC4A-EC9A5389037BQ34413000-40509D31-122B-4FDA-9B23-710D24B69A0CQ34459026-A33D6FAB-AFDE-4FF6-91A9-ABEF47AD3EB4Q34674612-8B8474AB-E592-402C-9353-CF59FE6C2FE2Q34914207-AB9780E8-39B9-463E-9EFC-8D2138670498Q35076957-74BCC693-9800-4D6E-A2E9-D9F4995E51A3Q35591453-196F3689-9A9A-4E08-A7D2-B6AF30246756Q35719211-05EFC0C9-D18E-4C9D-9696-549D5CEB0FB8Q35853498-6B03BD1E-1F05-4BB7-B010-F2F2752A56CAQ36240200-A52DD70A-31E3-4ECA-B349-81915648B412Q36349621-E86BC149-E0CB-4986-A9B1-3CEB71F54C20Q36400580-4E2B268D-559B-4313-A31E-E8684F25CB93Q36440361-A9C6CDFD-C84A-43DE-8A1A-387BFB5DF8BBQ36672863-0374A802-7D29-4CF5-B0DC-2532FC6911A1Q36707191-70D126BD-7052-4CDB-86F5-399F21A105CCQ37181670-D8AB46A3-DBF9-43B9-B1D3-C339B0BB61C1Q37409001-412B853F-5E3B-4466-A556-BA32B206410EQ37466085-0157F4D5-09AD-4F81-BDB7-40C3E2F73555Q37577437-106887A1-51AE-489C-9BE5-9071F28D73DFQ37940581-6AB1A351-AED8-415F-953E-AFC1811294BCQ37954005-225E3BC9-BAB0-47AF-9646-CCF3802B79D7Q38019465-A01F021C-A7BA-4188-95CD-21BAA0314239Q38112375-C8B92DB2-64DE-42CF-A6C0-6E20E919410AQ38241140-4BCBF931-AD9E-4692-B571-19346FC7A424Q38270688-266FA90F-6804-4E43-A6F2-E1F112150C05Q38497174-8F74BE12-640C-4F01-9060-5211D7E6700FQ38710638-F115EA76-6469-454D-ACC0-D496DD8FD0CDQ38778422-C05D41A1-E865-485F-8BCA-794F50661DFAQ38909557-986AB4E3-F391-4DF9-B8DC-08410627C460Q38953075-6AF7EFFE-2589-4C2E-A07C-0190071C5256Q39151688-A40F3937-1C93-4F66-932E-22111583D0FEQ39386513-808D9113-92B2-496B-9271-6F48B461FB08Q39727387-3C92558A-189C-4BDE-ACA4-AC86A76576A3Q40171791-2B085BEE-D85D-4921-81F1-005BCCEBE47CQ40297836-9B9B469E-8B6A-403C-9D80-C381333FD567
P2860
Locally administered ocular corticosteroids: benefits and risks.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Locally administered ocular corticosteroids: benefits and risks.
@ast
Locally administered ocular corticosteroids: benefits and risks.
@en
Locally administered ocular corticosteroids: benefits and risks.
@nl
type
label
Locally administered ocular corticosteroids: benefits and risks.
@ast
Locally administered ocular corticosteroids: benefits and risks.
@en
Locally administered ocular corticosteroids: benefits and risks.
@nl
prefLabel
Locally administered ocular corticosteroids: benefits and risks.
@ast
Locally administered ocular corticosteroids: benefits and risks.
@en
Locally administered ocular corticosteroids: benefits and risks.
@nl
P2093
P2860
P1433
P1476
Locally administered ocular corticosteroids: benefits and risks.
@en
P2093
Charles N J McGhee
Helen Danesh-Meyer
Simon Dean
P2860
P356
10.2165/00002018-200225010-00004
P577
2002-01-01T00:00:00Z
P6179
1020357593